New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection
- PMID: 29467963
- PMCID: PMC5805549
- DOI: 10.18632/oncotarget.24102
New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection
Abstract
Recent years have seen considerable progress in understanding the biochemistry of cancer. For example, more significance is now assigned to the tumor microenvironment, especially with regard to intercellular signaling in the tumor niche which depends on many factors secreted by tumor cells. In addition, great progress has been made in understanding the influence of factors such as neurotensin, growth differentiation factor-15 (GDF-15), sphingosine-1-phosphate (S1P), and infection with cytomegalovirus (CMV) on the 'hallmarks of cancer' in glioblastoma multiforme. Therefore, in the present work we describe the influence of these factors on the proliferation and apoptosis of neoplastic cells, cancer stem cells, angiogenesis, migration and invasion, and cancer immune evasion in a glioblastoma multiforme tumor. In particular, we discuss the effect of neurotensin, GDF-15, S1P (including the drug FTY720), and infection with CMV on tumor-associated macrophages (TAM), microglial cells, neutrophil and regulatory T cells (Treg), on the tumor microenvironment. In order to better understand the role of the aforementioned factors in tumoral processes, we outline the latest models of intratumoral heterogeneity in glioblastoma multiforme. Based on the most recent reports, we discuss the problems of multi-drug therapy in treating glioblastoma multiforme.
Keywords: cytomegalovirus; glioblastoma multiforme; growth differentiation factor-15; neurotensin; sphingosine-1-phosphate.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Figures







Similar articles
-
Expression of S1P metabolizing enzymes and receptors correlate with survival time and regulate cell migration in glioblastoma multiforme.Oncotarget. 2016 Mar 15;7(11):13031-46. doi: 10.18632/oncotarget.7366. Oncotarget. 2016. PMID: 26887055 Free PMC article.
-
Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells.Glia. 2014 Dec;62(12):1968-81. doi: 10.1002/glia.22718. Epub 2014 Jul 5. Glia. 2014. PMID: 25042636
-
Cytomegalovirus infection in early childhood may be protective against glioblastoma multiforme, while later infection is a risk factor.Med Hypotheses. 2012 May;78(5):657-8. doi: 10.1016/j.mehy.2012.02.003. Epub 2012 Mar 3. Med Hypotheses. 2012. PMID: 22385772
-
Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment.Front Oncol. 2016 Oct 17;6:218. doi: 10.3389/fonc.2016.00218. eCollection 2016. Front Oncol. 2016. PMID: 27800303 Free PMC article. Review.
-
The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture.Cancer Lett. 2014 Apr 28;346(1):1-5. doi: 10.1016/j.canlet.2013.12.003. Epub 2013 Dec 11. Cancer Lett. 2014. PMID: 24333730 Review.
Cited by
-
Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.Cancer Rep (Hoboken). 2019 Dec;2(6):e1220. doi: 10.1002/cnr2.1220. Epub 2019 Nov 11. Cancer Rep (Hoboken). 2019. PMID: 32729241 Free PMC article.
-
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.Int J Mol Sci. 2022 Jan 24;23(3):1311. doi: 10.3390/ijms23031311. Int J Mol Sci. 2022. PMID: 35163235 Free PMC article. Review.
-
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme.Front Oncol. 2022 Apr 19;12:818447. doi: 10.3389/fonc.2022.818447. eCollection 2022. Front Oncol. 2022. PMID: 35515137 Free PMC article. Review.
-
GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer.J Cancer. 2021 Jan 1;12(4):1125-1132. doi: 10.7150/jca.50376. eCollection 2021. J Cancer. 2021. PMID: 33442410 Free PMC article. Review.
-
Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin.Biology (Basel). 2024 Oct 21;13(10):846. doi: 10.3390/biology13100846. Biology (Basel). 2024. PMID: 39452154 Free PMC article. Review.
References
-
- Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. - PubMed
-
- Chen J, Xu T. Recent therapeutic advances and insights of recurrent glioblastoma multiforme. Front Biosci (Landmark Ed) 2013;18:676–684. - PubMed
-
- Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources